ArticleScientific reports2026
Taurine stimulates EPO production in feline renal cells through the HIF pathway.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) affects approximately 30% of elderly felines, impairing erythropoietin (EPO) secretion and leading to anemia, which significantly compromises feline health. Betaine, docosahexaenoic acid (DHA), and taurine are bioactive compounds known to modulate physiological processes, exhibiting anti-inflammatory and immunomodulatory properties. This study aimed to investigate their potential effects on EPO secretion in renal cells and their therapeutic potential for hematopoietic system improvement and anemia treatment. Two feline renal cell lines, PETCC191 and PETCC3002, were cultured and treated with betaine, DHA, and taurine. EPO expression was analyzed using western blot (WB) and quantitative reverse transcription PCR (qRT-PCR). EPO secretion was quantified by enzyme-linked immunosorbent assay (ELISA). The involvement of the HIF1α pathway was examined using the HIF1α inhibitor YC-1. Among the three compounds, taurine significantly upregulated both mRNA and protein levels of EPO and enhanced its secretion in both PETCC191 and PETCC3002 cells, even under hypoxic conditions. Mechanistic studies revealed that taurine-mediated EPO production in feline renal cells occurs through the HIF1α pathway. Our findings demonstrate that taurine significantly enhances the synthesis and secretion of EPO in feline renal cells, suggesting its potential as a renal protective agent and a promising bioactive compound for the treatment of renal anemia in felines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.